ST. LOUIS, April 27, 2017 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 first quarter ended March 31, 2017 on Monday, May 8, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.

What: Stereotaxis first quarter 2017 financial results conference call
   
When: Monday, May 8th at 10:00 a.m. Eastern Time (7:00 a.m. PT)
   
Dial In Number: To access the live call, dial 877-675-4756 (US and Canada) or 719-325-4839 (International) and give the participant pass code 3960816.
   
Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com 
   
Call Replay: A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Monday, May 15, 2017. To access the replay dial-in information, please click here.

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.

CONTACT: Company Contacts:                                                                         
David L. Fischel
Chairman and Acting Chief Executive Officer
Martin C. Stammer                                                                             
Chief Financial Officer
[email protected]